The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | The current standard of care for patients with essential thrombocythemia
Harinder Gill, MBBS, PDipID, MD, MRCP, FRCP, FRCPath, FHKCP, FHKAM, The University of Hong Kong, Hong Kong, China, gives an overview of the current standard of care (SOC) for essential thrombocythemia (ET), highlighting that treatment approaches depend on the patient’s risk of thrombosis. Dr Gill then discusses treatment strategies available to patients with both lower- and higher-risk disease, including aspirin, cytoreductive therapy, and ropeginterferon alfa-2a. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
